Immune checkpoint inhibitors targeting programmed cell death receptor 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have substantially improved clinical outcomes in multiple tumor types (1–9). This evidence concerns the gene CD274 and neoplasm.